Free Trial
NASDAQ:INVA

Innoviva (INVA) Stock Price, News & Analysis

Innoviva logo
$17.35 -0.10 (-0.57%)
Closing price 10/10/2025 04:00 PM Eastern
Extended Trading
$17.26 -0.09 (-0.52%)
As of 10/10/2025 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Innoviva Stock (NASDAQ:INVA)

Advanced

Key Stats

Today's Range
$17.23
$17.93
50-Day Range
$17.20
$20.92
52-Week Range
$16.67
$22.00
Volume
534,757 shs
Average Volume
764,988 shs
Market Capitalization
$1.09 billion
P/E Ratio
55.97
Dividend Yield
N/A
Price Target
$37.60
Consensus Rating
Moderate Buy

Company Overview

Innoviva Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
95th Percentile Overall Score

INVA MarketRank™: 

Innoviva scored higher than 95% of companies evaluated by MarketBeat, and ranked 54th out of 958 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Innoviva has received a consensus rating of Moderate Buy. The company's average rating score is 2.71, and is based on 4 buy ratings, 1 hold rating, and 1 sell rating.

  • Upside Potential

    Innoviva has a consensus price target of $37.60, representing about 116.7% upside from its current price of $17.35.

  • Amount of Analyst Coverage

    Innoviva has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Innoviva's stock forecast and price target.
  • Earnings Growth

    Earnings for Innoviva are expected to grow by 369.70% in the coming year, from $0.33 to $1.55 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Innoviva is 55.97, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 230.98.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Innoviva is 55.97, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 85.27.

  • Price to Book Value per Share Ratio

    Innoviva has a P/B Ratio of 1.57. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Innoviva's valuation and earnings.
  • Percentage of Shares Shorted

    10.61% of the float of Innoviva has been sold short.
  • Short Interest Ratio / Days to Cover

    Innoviva has a short interest ratio ("days to cover") of 8.
  • Change versus previous month

    Short interest in Innoviva has recently decreased by 1.78%, indicating that investor sentiment is improving.
  • Dividend Yield

    Innoviva does not currently pay a dividend.

  • Dividend Growth

    Innoviva does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    10.61% of the float of Innoviva has been sold short.
  • Short Interest Ratio / Days to Cover

    Innoviva has a short interest ratio ("days to cover") of 8.
  • Change versus previous month

    Short interest in Innoviva has recently decreased by 1.78%, indicating that investor sentiment is improving.
  • News Sentiment

    Innoviva has a news sentiment score of 0.82. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 8 news articles for Innoviva this week, compared to 4 articles on an average week.
  • Search Interest

    12 people have searched for INVA on MarketBeat in the last 30 days. This is an increase of 33% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Innoviva insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 2.25% of the stock of Innoviva is held by insiders.

  • Percentage Held by Institutions

    99.12% of the stock of Innoviva is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Innoviva's insider trading history.
Receive INVA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Innoviva and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

INVA Stock News Headlines

INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off
Right now, we’re witnessing a monumental shift in the world.tc pixel
Innoviva initiated with a Sell at Goldman Sachs
Where is Innoviva (INVA) Headed According to Analysts?
See More Headlines

INVA Stock Analysis - Frequently Asked Questions

Innoviva's stock was trading at $17.35 at the start of the year. Since then, INVA shares have increased by 0.0% and is now trading at $17.35.

Innoviva, Inc. (NASDAQ:INVA) issued its quarterly earnings results on Wednesday, August, 6th. The biotechnology company reported $0.77 earnings per share for the quarter, topping analysts' consensus estimates of $0.57 by $0.20. The biotechnology company had revenue of $100.28 million for the quarter, compared to analysts' expectations of $87.10 million. Innoviva had a trailing twelve-month return on equity of 18.67% and a net margin of 10.44%.

Innoviva's top institutional shareholders include Voya Investment Management LLC (0.02%) and Toth Financial Advisory Corp (0.01%).
View institutional ownership trends
.

Shares of INVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Innoviva investors own include NVIDIA (NVDA), Meta Platforms (META), Tesla (TSLA), Advanced Micro Devices (AMD), JPMorgan Chase & Co. (JPM), Netflix (NFLX) and Visa (V).

Company Calendar

Last Earnings
8/06/2025
Today
10/10/2025
Next Earnings (Estimated)
11/05/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Large Cap Pharma
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:INVA
Previous Symbol
NASDAQ:THRX
CIK
1080014
Employees
100
Year Founded
1996

Price Target and Rating

High Price Target
$55.00
Low Price Target
$17.00
Potential Upside/Downside
+116.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.71
Research Coverage
7 Analysts

Profitability

EPS (Trailing Twelve Months)
$0.31
Trailing P/E Ratio
55.97
Forward P/E Ratio
52.58
P/E Growth
N/A
Net Income
$23.39 million
Net Margins
10.44%
Pretax Margin
17.71%
Return on Equity
18.67%
Return on Assets
9.92%

Debt

Debt-to-Equity Ratio
0.36
Current Ratio
2.64
Quick Ratio
2.44

Sales & Book Value

Annual Sales
$370.23 million
Price / Sales
2.95
Cash Flow
$3.42 per share
Price / Cash Flow
5.07
Book Value
$11.03 per share
Price / Book
1.57

Miscellaneous

Outstanding Shares
63,021,000
Free Float
61,603,000
Market Cap
$1.09 billion
Optionable
Optionable
Beta
0.40

Social Links

Analysts Agree—These Gold Picks Outshine the Rest Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

This page (NASDAQ:INVA) was last updated on 10/11/2025 by MarketBeat.com Staff
From Our Partners